Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages
about
Antimycobacterial activities of novel levofloxacin analoguesIn vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosisComparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosisActivity of levofloxacin in a murine model of tuberculosisAlterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatisComparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophagesBacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophagesIn vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosisSusceptibility testing of Mycobacterium avium complex isolatesRoxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige miceActivities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige miceSpectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofaziminePharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patientsFluoroquinolones and tuberculosis.Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium aviumPharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cellsIncreased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell modelIn vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium.In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.Intralobar sequestration with tuberculous infection confined to the sequestrated lung.New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.Design synthesis and antibacterial activity studies of new thiadiazoloquinolone compounds.Synthesis and Antibacterial Activity of Some Novel 4-Oxopyrido[2,3-a]phenothiazines
P2860
Q28344486-27810B29-488B-4748-8DAC-D28BA055C7A4Q28367763-36A78136-6362-431D-8FA1-2E1C884B1128Q28368212-25D9E27E-74B3-41BA-8E0E-32C9E1791F6CQ28369090-8BF3FA67-C7BB-4FFE-BF40-A496FF592AA5Q28373280-1E01E009-0AD5-479B-BD9F-A52B3F0723A2Q28378747-221171FE-E538-4DAC-A83D-130A3D246AF2Q28379003-49FA1B93-FE24-4136-9ACA-85493E25936CQ28379137-12296889-0505-464A-9737-965ECF0DD93FQ28379189-751DFF34-4548-42CA-AEE5-40AE2DCB3021Q28379202-3AE0631B-13A3-4FFF-9B19-CE2DC556E741Q28379216-248A7DA0-A3EC-4AA3-AF39-7A35DFF4B7D2Q28379290-52358DF4-720C-46C6-9B25-8683B0E49682Q33977737-9C512777-6C8E-451E-88AB-7656ADB229C7Q34519143-D197E9DE-B64F-4174-AB21-3507003E79B2Q34524078-44DF48D7-DF2D-455B-ACCB-9D1AE28F81A7Q35822975-AF7ECB53-08DB-465F-9C42-CD19560CF17DQ38845761-3923E538-ECF6-400A-A8A5-835338954B93Q39469480-06CB6E94-8FD9-4F12-972C-EDD9842D94B3Q39475630-863AAD5D-41AA-4F69-8230-A92FAB169661Q39651212-CE0B3FFE-62AA-4273-ADB8-8894A65F66A6Q39779350-8EAD9458-DA0A-4ECB-8563-155DB806584EQ39780472-D13DA1AA-D3AD-4ACB-A06D-DE67FAA3BD53Q40279724-4B87CDB8-DA94-4ED7-A540-9DF9EEA43FB1Q45242783-46339F97-0DD9-4771-886C-3AB2858DD872Q47594312-0E7D50FC-8006-41E7-B989-0A9BFEB3AA61Q54295509-83C58DFA-5CA3-49DA-8564-E012EBC7D4EEQ57787870-91D222A8-BC25-4BB9-8B66-A4D53FDE8ED0
P2860
Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@ast
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@en
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@nl
type
label
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@ast
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@en
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@nl
prefLabel
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@ast
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@en
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@nl
P2093
P2860
P356
P1476
Inhibitory and bactericidal ac ...... vitro and in human macrophages
@en
P2093
P2860
P304
P356
10.1128/AAC.38.5.1161
P407
P577
1994-05-01T00:00:00Z